胃力康与多潘立酮治疗反流性食管炎临床疗效和安全性比较

Comparison of clinical efficacy and safety of weilikang and domperidone in treatment of reflux esophagitis

目的 :观察胃力康治疗反流性食管炎的临床疗效和安全性。方法 :80例反流性食管炎患者随机分为胃力康胃力康组 4 0例 ,用胃力康颗粒 10g ,po ,tid ;多潘立酮多潘立酮组 4 0例 ,用多潘立酮 10mg ,po ,tid ,疗程均为 6wk。结果 :胃力康在治疗 6wk后打嗝、反酸、反食、胃部不适和吞咽后胸痛等症状改善 ,总有效率为 85 .0 % ;多潘立酮总有效率为60 .0 % (P <0 .0 5 )。结论 :胃力康能明显缓解反流性食管炎患者的临床症状 ,疗效优于多潘立酮 ,不良反应轻微 ,是治疗反流性食管炎有效。

AIM: To compare the clinical efficacy and safety of weilikang and domperidone in treatment of reflux esophagitis. METHODS: 80 cases of patients with reflux esophagitis were divided into two groups: one group patients were treated with Weilikang 10 g, po, tid; the other group ones was given domperidone, 10 mg, po, tid. The period of treatment all was 6 weeks. RESULTS: After 6 weeks, the total efficacy rates of weilikang and domperidone were 85.0 % and 60.0 % (P< 0.05 ), respectively. CONCLUSION: Weilikang can obviously relieve the clinical symptoms of patients with reflux esophagitis, its efficacy is better than that of domperidone, and the adverse reaction is slight.